What is MAPS Public Benefit?
Founded in 1986, MAPS (Multidisciplinary Association for Psychedelic Studies) is a pioneering 501(c)(3) non-profit research and educational organization. Its core focus is on advancing the understanding and therapeutic application of psychedelics and marijuana. The organization has been instrumental in funding extensive research and educational initiatives aimed at establishing a framework for the safe and effective integration of these substances into medical and societal practices. MAPS's work spans critical areas of drug development, clinical trials, and policy reform, positioning it at the forefront of the evolving landscape of psychedelic medicine.
How much funding has MAPS Public Benefit raised?
MAPS Public Benefit has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in MAPS Public Benefit
PPP
Public-Private Partnership
What's next for MAPS Public Benefit?
With substantial backing, MAPS Public Benefit is poised to accelerate its research and advocacy efforts. The large-scale, late-stage funding indicates a transition towards broader implementation and potentially scaling up its initiatives. Future developments are likely to focus on advancing clinical research, expanding educational outreach, and influencing regulatory frameworks to support the wider acceptance and therapeutic use of psychedelics. This strategic investment signals strong confidence in MAPS's long-term vision and its capacity to drive significant advancements in psychedelic-assisted therapies.
See full MAPS Public Benefit company page
